Search - tctmd.com

Displaying 1 - 20 of 31

Sort: Relevancy | Date

Presentation THT 2025

HFpEF in Focus: The Scientific Rationale for the Confirmatory RESPONDER HF Trial

Presenter: Sanjiv Shah

February 12, 2025

Presentation THT 2025

What Endpoints are Relevant for Evaluating how Interatrial Shunts Provide Clinical Benefit: Hemodynamic Exercise Testing and Beyond

Presenter: Sanjiv Shah

February 11, 2025

Presentation THT 2025

Atrial Shunt for Heart Failure With Preserved and Mildly Reduced Ejection Fraction: Five-Year Outcomes in the REDUCE LAP-HF II Trial

Presenter: Sanjiv Shah

February 11, 2025

Presentation THT 2025

How Regulation of Stressed Blood Volume at Rest and Exercise Contributes to HFpEF Symptomatology

Presenter: Sanjiv Shah

February 11, 2025

Presentation TCT 2024

HFpEF: Devices on the Rise or Fall?

Presenter: Sanjiv Shah

October 28, 2024

Presentation THT 2024

PH-HFpEF: Levosimendan

Presenter: Sanjiv J. Shah

March 06, 2024

Presentation THT 2024

Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure with Preserved Ejection Fraction: REBALANCE-HF Randomized Trial 12-Month Results

Presenter: Sanjiv J. Shah

March 05, 2024

Presentation THT 2024

Patient Selection Considerations for Trials of Interatrial Shunts

Presenter: Sanjiv J. Shah

March 05, 2024

Presentation THT 2024

HFpEF Diagnosis and Treatment: : Where Do We Stand in 2024?

Presenter: Sanjiv J. Shah

March 04, 2024

Presentation THT 2024

Right Heart Function and Flow Dynamics with Different Left-to-Right Shunt Approaches

Presenter: Sanjiv J. Shah

March 04, 2024

Presentation TCT 2023

Interatrial Shunts: Devices, Clinical Results, and Future Prospects

Presenter: Sanjiv Shah

October 26, 2023

Presentation TCT 2023

Atrial Secondary MR or TR in HFpEF: How to Treat

Presenter: Sanjiv Shah

October 24, 2023

Presentation THT 2023

Update on the Phase 2 REBALANCE-HF Trial of SAVM for HFpEF/HFmrEF: Lessons Learned and Future Directions

Presenter: Sanjiv Shah

March 21, 2023

Presentation THT 2023

IASDs: What We Know and What We Don't Know

Presenter: Sanjiv Shah

March 20, 2023

Presentation THT 2023

Interventional Therapies for HFpEF

Presenter: Sanjiv Shah

March 20, 2023

Presentation TVT 2022

Exercise PVR, A Key Predictor of Benefit of Atrial Shunt Therapy in HFpEF?

Presenter: Sanjiv Shah

June 10, 2022

Presentation TVT 2022

What (Else) Have We Learned From REDUCE-LAP II?

Presenter: Sanjiv Shah

June 10, 2022

Presentation THT 2022

AXON Therapeutics

Presenter: Sanjiv J. Shah

February 02, 2022

Presentation THT 2022

Physiological Phenotyping

Presenter: Sanjiv Shah

February 01, 2022

Presentation THT 2022

Current status of the REBALANCE-HF US FDA randomized feasibility clinical trial in HFpEF

Presenter: Sanjiv Shah

February 01, 2022

Advertisement

HFpEF in Focus: The Scientific Rationale for the Confirmatory RESPONDER HF Trial

What Endpoints are Relevant for Evaluating how Interatrial Shunts Provide Clinical Benefit: Hemodynamic Exercise Testing and Beyond

Atrial Shunt for Heart Failure With Preserved and Mildly Reduced Ejection Fraction: Five-Year Outcomes in the REDUCE LAP-HF II Trial

How Regulation of Stressed Blood Volume at Rest and Exercise Contributes to HFpEF Symptomatology

HFpEF: Devices on the Rise or Fall?

PH-HFpEF: Levosimendan

Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure with Preserved Ejection Fraction: REBALANCE-HF Randomized Trial 12-Month Results

Patient Selection Considerations for Trials of Interatrial Shunts

HFpEF Diagnosis and Treatment: : Where Do We Stand in 2024?

Right Heart Function and Flow Dynamics with Different Left-to-Right Shunt Approaches

Interatrial Shunts: Devices, Clinical Results, and Future Prospects

Atrial Secondary MR or TR in HFpEF: How to Treat

Update on the Phase 2 REBALANCE-HF Trial of SAVM for HFpEF/HFmrEF: Lessons Learned and Future Directions

IASDs: What We Know and What We Don't Know

Interventional Therapies for HFpEF

Exercise PVR, A Key Predictor of Benefit of Atrial Shunt Therapy in HFpEF?

What (Else) Have We Learned From REDUCE-LAP II?

AXON Therapeutics

Physiological Phenotyping

Current status of the REBALANCE-HF US FDA randomized feasibility clinical trial in HFpEF

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content